$0.47
2.09%
Downside
Day's Volatility :11.26%
Upside
9.37%
2.23%
Downside
52 Weeks Volatility :97.95%
Upside
97.9%
Period | Genprex Inc | Index (Russel 2000) |
---|---|---|
3 Months | -80.81% | 0.0% |
6 Months | -88.94% | 0.0% |
1 Year | -97.68% | 0.0% |
3 Years | -99.61% | -22.3% |
Market Capitalization | 1.3M |
Book Value | $1.7 |
Earnings Per Share (EPS) | -14.84 |
Wall Street Target Price | 8.75 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -145.94% |
Return On Equity TTM | -318.88% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -26.3M |
Diluted Eps TTM | -14.84 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -5.62 |
EPS Estimate Next Year | -2.18 |
EPS Estimate Current Quarter | -2.3 |
EPS Estimate Next Quarter | -1.13 |
What analysts predicted
Upside of 1761.7%
Sell
Neutral
Buy
Genprex Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Genprex Inc | -67.35% | -88.94% | -97.68% | -99.61% | -98.66% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Genprex Inc | NA | NA | NA | -5.62 | -3.19 | -1.46 | NA | 1.7 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Genprex Inc | Buy | $1.3M | -98.66% | NA | 0.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Genprex Inc
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 134.8%
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 168.8%
Armistice Capital, LLC
Vanguard Group Inc
Geode Capital Management, LLC
BlackRock Inc
Tower Research Capital LLC
Morgan Stanley - Brokerage Accounts
genprex is mapping the future of cancer care. genprex's mission is to address the unmet medical needs of a growing population of cancer patients worldwide, through the development of a novel class of cancer drugs: immunogene therapy. our revolutionary clinical-stage products work synergistically with other approved and pipeline drugs to expand clinical indications for various cancers. about oncoprex® and lung cancer lung cancer is the second most common cancer in the u.s. but the leading cause of cancer death. there are approximately 225,000 new lung cancer cases in the u.s. per year and 1.8 million worldwide. the 5-year survival rate of stage iv non-small cell lung cancer (nsclc) is less than 1%, and treatment options beyond chemotherapy are lacking. approved nsclc targeted treatment options outside of chemo/radiation therapies only benefit a minority of patients. oncoprex® may now fill that gap by offering a targeted treatment option for a majority of nsclc patients. oncoprex® is cur
Organization | Genprex Inc |
Employees | 21 |
CEO | Dr. Mark S. Berger M.D. |
Industry | Health Technology |
A Spac I Acquisition Corp
$0.47
-5.79%
Keyarch Acquisition Corp
$0.47
-5.79%
Connexa Sports Technologies Inc
$0.47
-5.79%
Us Value Etf
$0.47
-5.79%
First Wave Biopharma Inc
$0.47
-5.79%
Global X Msci Next Emerging
$0.47
-5.79%
Fat Projects Acquisition Corp
$0.47
-5.79%
Capital Link Global Fintech
$0.47
-5.79%
Applied Uv Inc
$0.47
-5.79%